+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


World Companian Diagnostic Technologies Market - Opportunities and Forecasts, 2014 - 2022

  • ID: 3773419
  • Report
  • Region: Global
  • 107 pages
  • Allied Analytics LLP
1 of 4

Companion diagnostics are in-vitro diagnostics that provide information about therapeutic responses of patients for a specific treatment. Companion diagnostics market is still nascent, and it is projected to reach $3.5 billion by 2020 from a base value of $1.1 billion in 2013, growing at a CAGR of 20% during 2014 to 2020. The global companion diagnostic market is segmented based on indication, technology and geography (North America, Europe, Asia Pacific and LAMEA). Geographically, LAMEA is the fastest growing region. The key drivers for this market are the increase in the discovery of biomarkers and co-development of drug and corresponding diagnostic. However, cost associated with developing drugs could impede the growth of this market. Opportunities for this market lie in developing companion diagnostics for various central nervous system conditions and hereditary conditions.

Companion Diagnostics Indication Market Analysis

Companion diagnostics is segmented on the basis of its use for indications such as oncology, cardiovascular conditions, central nervous system indications, inflammation and virology. Oncology is the highest revenue generating segment, as majority of the companion diagnostics have been developed for detection of various cancer biomarkers. The key driver for this market is an increase in research and development of targeted drugs, which require a corresponding companion diagnostic.

Companion Diagnostics Technology Market Analysis

Companion diagnostics technology market is segmented into Immunohistochemistry and Molecular diagnostics. Molecular diagnostics would be the fastest growing and highest revenue generator, mainly due to the use of techniques such as real time PCR, In Situ Hybridization and next generation sequencing. Other factors contributing to the growth is technological advancements in molecular diagnostics, which has resulted in increased accuracy and precision and also reduced cost of testing using these methods.

Companion Diagnostics Geography Market Analysis

Companion Diagnostics market has been segmented geographically into North America, Europe, Asia Pacific and LAMEA. North America has the major market share of 43.97% followed by Europe, which accounted for about 38% of the overall CD market in 2013. North America and Europe together accounted for over 82% in the global CD market in 2013 and they would continue to be the major markets through 2020. This is mainly due to the increasing incidence of cancer and other diseases and higher health care awareness in these regions.

Competitive Analysis

A study of some of the key players has showed that majority of the companies in this market are focusing on collaborations with drug companies. Companion diagnostics is a emerging market and companies are collaborating with drug companies to develop companion diagnostics for their pipeline drugs, which are in developing phase. Approvals for companion diagnostics are the second most popular strategy. Companies profiled in this report include Dako (Agilent Technologies), Qiagen, Roche, Abbott Laboratories, Inc., Ventana Medical Systems, bioMerieux, Myriad Genetics, Inc., Resonance Health Ltd., Leica Microsystems, and Life Technologies.

High Level Analysis

The report is focusing on the trends in technology and diagnosis of various indications, which are driving the growth of the companion diagnostics market. Analysis of the market based on porters five force model shows that the bargaining power of the suppliers is high as the products produced are highly differentiated. The threat of new entrants is low as significant research and development is required for developing diagnostic tests. Apart from the R&D requirements, the investment required is also high. These factors make it difficult for new companies to enter the market. The threat of substitutes is low in this market as companion diagnostics are developed for specific biomarkers and the products are highly differentiated. Competition in this market is moderate as the market is still emerging and there are a few companies in the market. Government regulations are favoring use of companion diagnostics for determining a particular treatment. Companies are focusing on collaborations with pharmaceutical companies as a key strategy to gain competitive advantage.

Reason for doing the study

Companion diagnostics are an important aspect of the personalized treatment approach and are essential for predicting the therapeutic response to a particular drug. With increasing awareness among the population and rising incidences of cancer, companion diagnostics would become an essential factor for targeted therapeutic approach. More and more companies are developing targeted therapeutics products and companion diagnostics is an integral part of their strategy.


  •     In-depth analysis of the companion diagnostic market by technology and indications give a clear idea of the scope of this market
  •     Analysis of the market by geography would help in making region specific plans
  •     Estimations for period of 2013 to 2020 have been given, taking into consideration the current market scenario and future trends, which would give a clearer picture of the potential of the market
  •     Porter’s five force model and SWOT analysis would help in a deeper understanding of the market and help in making strategic decisions
  •     Top factors impacting the market would help in making decisions for business development



  •     Oncology
  •     Cardiovascular
  •     Central Nervous System
  •     Auto immune & Inflammation
  •     Virology
  •     Others


  •     Immunohistochemistry
  •     Molecular diagnostics
  •     In situ Hybridization
    •             FISH
    •             CISH
  •     Real time PCR
  •     Gene Sequencing


  •     North America
  •     Europe
  •     Asia Pacific
  •     LAMEA
Note: Product cover images may vary from those shown
2 of 4

1.1 Report description
1.2 Key market segments
1.3 Research methodology
1.3.1 Secondary research
1.3.2 Primary research
1.3.3 Analyst tools and models
3.1 Market Definition and Scope
3.2 Companion Diagnostics for Metabolic Diseases
3.3 Novel trends and technologies in companion diagnostics assay development
3.4 Companion diagnostics as a new trend in personalized medicine
3.5 Biomarkers market as basis for the companion diagnostics industry
3.6 Key Findings
3.6.1 Top Factors Impacting The Companion Diagnostic Market
3.6.2 Top Winning Strategies
3.7 Porter’s five forces analysis
3.7.1 High switching cost leads to higher bargaining power of suppliers
3.7.2 Highly differentiated products leads to lower bargaining power of buyers
3.7.3 Specificity of diagnostics lowers the threat of substitutes
3.7.4 Higher capital investment leads to lesser threat of entrants
3.7.5 Few competitors leads to low competition among players
3.8 Government Regulations
3.8.1 FDA regulations
3.8.2 Europe
3.8.3 Japan
3.8.4 China
3.9 Value Chain Analysis
3.10 Case Study
3.11 Drivers
3.11.1 Increased popularity of Personalized medicine
3.11.2 Increasing cases of adverse drug reactions(ADRs)
3.11.3 Increase in the Discovery of Biomarkers as drug targets.
3.11.4 Rising success of co-development drugs speedily approved by the FDA
3.11.5 Technological advancements
3.11.6 Rising incidences of diseases
3.12 Restraints
3.12.1 High Cost in research and development of drugs Economic and scientific obstacles
3.12.2 Opportunities Opportunities in treatment of neurodegenerative diseases Companion diagnostics for hereditary mutations
4.1 Oncology
4.1.1 Companion diagnostics oncology market by geography,
4.1.2 Breast Cancer companion diagnostics breast cancer market by geography
4.1.3 Lung Cancer companion diagnostics lung cancer market by geography
4.1.4 Colorectal Cancer companion diagnostics Colorectal Cancer market by geography
4.1.5 Gastric cancer companion diagnostics Gastric Cancer market by geography
4.1.6 Melanomas companion diagnostics Melanoma market by geography
4.2 Inflammation and Autoimmune diseases
4.2.1 Companion diagnostics inflammation market by geography
4.3 Companion diagnostics in cardiovascular diseases
4.3.1 Companion diagnostics tests for warfarin
4.3.2 Companion diagnostics cardiovascular market by geography
4.4 Companion diagnostics in CNS disorders
4.4.1 Companion diagnostics CNS market by geography
4.5 Companion diagnostics tests in virology diseases
4.5.1 Companion diagnostics virology market by geography
4.6 Others
4.6.1 Companion diagnostics others market by geography
5.1 Companion diagnostics technology market by geography
5.2 Immunohistochemistry
5.2.1 Companion diagnostics Immmunohistochemistry market by geography
5.3 Molecular Diagnostics
5.3.1 Companion diagnostics molecular diagnostics market by types
5.3.2 Companion diagnostics Molecular Diagnostics market by geography
5.3.3 In-situ Hybridization Fluorescent In-situ Hybridization(FISH) CISH (Chromogenic In-Situ Hybridization) Companion diagnostics In situ Hybridization market by geography
5.3.4 Real Time PCR Companion diagnostics RT PCR market by geography
5.3.5 Gene Sequencing Companion diagnostics Sequencing market by geography
5.3.6 Others Others molecular companion diagnostics market by geography
6.1 North America
6.1.1 Companion diagnostics North America market by indication
6.2 Europe
6.2.1 Companion diagnostics Europe market by indication
6.3 Asia Pacific
6.3.1 Companion diagnostics Asia Pacific market by indication
6.4 RoW
6.4.1 Companion diagnostics RoW market by indication
7.1 Qiagen
7.1.1 Company Overview:
7.1.2 Company Snapshot
7.1.3 Business Performance
7.1.4 Strategy move and development    Principal strategies Collaborations    Secondary Strategies Approval
7.1.5 SWOT Analysis of Qiagen
7.2 Dako (Agilent Technologies)
7.2.1 Company Overview
7.2.2 Company Snapshot
7.2.3 Business Performance
7.2.4 Strategic Moves and Development  Principal strategies Collaboration  Secondary Strategies Approval
7.2.5 SWOT Analysis of Dako
7.3 Roche
7.3.1 Company overview
7.3.2 Company Snapshot
7.3.3 Business Performance
7.3.4 Strategies move and development
7.3.5 SWOT analysis of Roche
7.4 Abbott Laboratories, Inc.
7.4.1 Company Overview
7.4.2 Company Snapshot
7.4.3 Business Performance
7.4.4 Principal Strategies Collaboration
7.4.5 SWOT Analysis of Abbot
7.5 BioMerieux
7.5.1 Company Overview
7.5.2 Company snapshot:
7.5.3 Business Performance
7.5.4 Strategies and development Approval
7.5.5 SWOT Analysis of BioMerieux,
7.6 Ventana Medical Systems
7.6.1 Company Profile
7.6.2 Company Snapshot
7.6.3 Business Performance
7.6.4 Strategies and development 
7.6.5 SWOT Analysis of Ventana
7.7 Myriad Genetics, Inc.
7.7.1 Company Overview
7.7.2 Company snapshot
7.7.3 Business Performance
7.7.4 Strategies  and  development
7.7.5 SWOT Analysis of Myraid
7.8 Resonance Health Ltd
7.8.1 Company Overview
7.8.2 Company Snapshot
7.8.3 Strategies move and development
7.8.4 SWOT Analysis of Ferriscan
7.9 Leica Microsystems
7.9.1 Company overview
7.9.2 Company Snapshot
7.9.3 Strategies move and Development
7.9.4 SWOT Analysis of Leica Microsystems
7.10 Life Technologies
7.10.1 Company Overview
7.10.2 Company Snapshot
7.10.3 Business performance
7.10.4 Strategies move and Development
7.10.5 SWOT Analysis of Life Technologies

List of Tables

Table 1 Global Companion Diagnostics Market By Indication, 2013-2020 ($Million)
Table 2 Companion Diagnostics Indication Market By Geography, 2013-2020 ($Million)
Table 3 Global Companion Diagnostics Market By Oncology, 2013-2020, ($Million)
Table 4 Companion Diagnostics Oncology Market By Geography, 2013-2020, ($Million)
Table 5 Companion Diagnostics Breast Cancer Market By Geography, 2013-2020 ($Million)
Table 6 Companion Diagnostics Lung Cancer Market By Geography, 2013-2020 ($Million)
Table 7 Companion Diagnostics Colorectal Cancer Market By Geography, 2013-2020 ($Million)
Table 8 Companion Diagnostics Gastric Cancer Market By Geography, 2013-2020 ($Million)
Table 9 Companion Diagnostics Melanoma Market By Geography, 2013-2020 ($Million)
Table 10 Companion Diagnostics Inflammation Market By Geography, 2013-2020 ($Million)
Table 11 Companion Diagnostics Cardiovascular Market By Geography, 2013-2020 ($Million)
Table 12 Companion Diagnostics Cns Market By Geography, 2013-2020 ($Million)
Table 13 Companion Diagnostics Virology Market By Geography, 2013-2020 ($Million)
Table 14 Companion Diagnostics Others Market By Geography, 2013-2020 ($Million)
Table 15 Companion Diagnostics Technology Market By Technology 2013-2020 ($Million)
Table 16 Companion Diagnostics Technology Market By Geography, 2013-2020 ($Million)
Table 17 Companion Diagnostics Immmunohistochemistry Market By Geography, 2013-2020 ($Million)
Table 18 Companion Diagnostics Molecular Diagnostics Market By Types 2013-2020 ($Million)
Table 19 Companion Diagnostics Molecular Diagnostics Market By Geography, 2013-2020 ($Million)
Table 20 Companion Diagnostics In Situ Hybridization Market By Geography, 2013-2020 ($Million)
Table 21 Companion Diagnostics Rt Pcr Market By Geography, 2013-2020 ($Million)
Table 22 Companion Diagnostics Sequencing Market By Geography, 2013-2020 ($Million)
Table 23 Others Molecular Companion Diagnostics Market By Geography, 2013-2020 ($Million)
Table 24 Companion Diagnostics Others Market By Geography, 2013-2020 ($Million)
Table 25 Companion Diagnostics North America Market, 2013-2020 ($Million)
Table 26 Companion Diagnostics Europe Market, 2013-2020 ($Million)
Table 27 Companion Diagnostics Asia-Pacific Market, 2013-2020 ($Million)
Table 28 Companion Diagnostics Row Market, 2013-2020 ($Million)
Table 29 Qiagen Snapshot
Table 30 Dako Company Snapshot
Table 31 Roche Company Snapshot
Table 32 Abbott Company Snapshot
Table 33 Biomerieux Company Snapshot
Table 34 Ventana Company Snapshot
Table 35 Myriad Company Snapshot
Table 36 Resonance Company Snapshot
Table 37 Leica Company Snapshot
Table 38 Life Technologies Company Snapshot

List of Figures

Fig.1 Companion Diagnostics As A New Trend In Personalized Medicine
Fig.2 Effectiveness Of Companion Diagnostics In Lung Cancer Patients
Fig.3 List Biomarkers And The Companion Diagnostics For Various Diseases
Fig.4 Top Factors Impacting The Companion Diagnostic Market
Fig.5 Top Winning Strategies
Fig.6 Value Chain Analysis
Fig.7 Financial Revenues By Business Units (2013)
Fig.8 Financial Revenues By Geography(2013)
Fig.9 SWOT Analysis Of Qiagen
Fig.10 Financial Revenue Of Dako, By Segment (2012)
Fig.11 SWOT Analysis Of Dako
Fig.12 Financial Revenue Of Dako, By Segment
Fig.13 Financial Revenue Of Dako, By Geography
Fig.14 SWOT Analysis Of Roche
Fig.15 Revenue By Business Segments
Fig.16 Revenue By Geography
Fig.17 SWOT Analysis Of Abbott
Fig.18 Financial Revenues By Geography
Fig.19 Financial Revenues By Technology
Fig.20 SWOT Analysis Of Biomerieux
Fig.21 SWOT Analysis Of Ventana
Fig.22 Revenue By Diagnostic Type
Fig.23 SWOT Analysis Of Myraid
Fig.24 SWOT Analysis Of Ferriscan
Fig.25 SWOT Analysis Of Leica Microsystems
Fig.26 Revenue By End Markets
Fig.27 SWOT Analysis Of Life Technologies

Note: Product cover images may vary from those shown
3 of 4


4 of 4

According to the research report titled "World Companion Diagnostic Market" the global companion diagnostic market is expected to reach$3.5 billion by 2020, and it would grow at a CAGR of 20% from 2014 to 2020.

Companion diagnostic (CD) is an in-vitro diagnostic technique that provides information about therapeutic responses of patient to a specific treatment. Companion diagnostics helpin identification of the patients who would benefit from the treatment using a certain therapeutic product which would result in improved treatment outcomes and decrease expenditure on healthcare. In addition, CD also helps in identifying the patient pool that is most likely to respond to the therapeutic treatment; therefore, rules out therapies that would be ineffective. Additionally, it also saves patients from adverse side effects due to ineffective therapies, leading to reduced cost. Rising incidence of cancer, increasing adverse reactions due to drugs and personalized treatment approach is pushing R&D efforts to focus on the development of targeted therapies. Technological advancement and discovery of new biomarkers is also driving growth of this market. However, coordinating the development of companion diagnostics and therapeutic products is a challenge for this market. Nevertheless, the increasing incidences of cancer, cardiovascular conditions, central nervous system conditions has resulted in significant investments in research and development of targeted therapies, which would need corresponding companion diagnostics and would be an opportunity for growth of this market.

Companion diagnostics market by indication is segmented into oncology, cardiovascular, CNS, autoimmune & inflammation, virology and others. Presently, the majority of the companion diagnostics has been developed for cancer and thus, it is the major revenue generating segment in the overall CD indication market. Companion diagnostics have been developed for breast cancer, lung cancer, colorectal cancer, gastric cancer and melanomas. Companion diagnostics for breast cancer is the highest revenue generator mainly because there has been an increase in the incidences of breast cancer and many companion diagnostics have been developed for detection of the HER/neu biomarker for breast cancer. As of now, companion diagnostics for cardiovascular conditions, central nervous system conditions , inflammation and autoimmune diseases and viral diseases are very few, with a majority still in the development stage; however, as more and more biomarkers are being discovered, there would be an increase in the development of new companion diagnostics.

Companion diagnostics market by technology is segmented into Immunohistochemistry and molecular diagnostics. Molecular diagnostics havebeen the most favored technology and it is expected that next generation sequencing and real-time PCR would drive the growth of this market owing to recent advancements in these technologies. The market is dominated by North America followed by Europe, as there is an increased healthcare awareness, significant investments in research & development and increasing incidences of cancer and other conditions in these regions. However, LAMEA is expected to grow at a significant rate, as there are growing incidences of cancer in these regions. There is also an increased awareness about healthcare, in the region; therefore, the usage of companion diagnostics would invariably rise. Ten leading companies dealing in companion diagnostics have been profiled and are Qiagen, Dako (Agilent Technologies), Roche, Abbott Laboratories, Inc., bioMerieux, Ventana Medical Systems, Myriad Genetics, Inc., Leica Microsystems, Resonance Health Ltd and Life Technologies. The key strategy followed by majority of the companies is collaborations with pharmaceutical companies for developing companion diagnostics for their pipeline drugs.

Note: Product cover images may vary from those shown
5 of 4

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.